MaxCyte announced the first patient has been dosed in its Phase I dose-escalation clinical trial in the United States with the company’s lead wholly-owned chimeric antigen receptor (CAR) therapeutic candidate, MCY-M11. The study is designed to evaluate MCY-M11, a mesothelin targeting CAR, in individuals with relapsed/refractory ovarian cancer and peritoneal mesothelioma.
{iframe}https://www.americanpharmaceuticalreview.com/1315-News/354417-MaxCyte-Begins-Dosing-in-First-Clinical-Trial-in-Solid-Tumors/{/iframe}